Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications

被引:1
作者
Liu, He-Nan [1 ]
Zhu, Ying [2 ]
Chi, Yuan [3 ]
Sun, Fei-Fei [4 ]
Shan, Li-Shen [5 ]
Wang, Ya-Tao [6 ]
Dai, Bing [5 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Ophthalmol, Shenyang, Peoples R China
[2] China Med Univ, Hosp 1, Dept Neurol, Shenyang, Peoples R China
[3] China Med Univ, Shengjing Hosp, Dept Radiol, Shenyang, Peoples R China
[4] China Med Univ, Shengjing Hosp, Dept Ultrasound, Shenyang, Peoples R China
[5] China Med Univ, Shengjing Hosp, Dept Pediat, Shenyang, Peoples R China
[6] Katholieke Univ Leuven, Rega Inst Med Res, Med Chem, Herestr 49 Box 1041, B-3000 Leuven, Belgium
关键词
Fluorine; Anti-cancer; Synthetic approaches; Clinical applications; Content; NEXT-GENERATION; INHIBITOR; DISCOVERY; EFFICACY; SAFETY; POTENT; PHARMACEUTICALS; PEXIDARTINIB; VEMURAFENIB; PEMIGATINIB;
D O I
10.1016/j.ejmech.2024.116722
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fluorine possesses distinctive chemical characteristics, such as its strong electron-withdrawing ability and small atomic size, which render it an invaluable asset in the design and optimization of pharmaceuticals. The utilization of fluorine-enriched medications for combating cancer has emerged as a prominent approach in medicinal chemistry and drug discovery, offering improved clinical outcomes and enhanced pharmacological properties. This comprehensive review explores the synthetic approaches and clinical applications of approved 22 representative fluorinated anti-cancer drugs from 2019 to present, shedding light on their historical development, brand names, drug target activity, mechanism of action, preclinical pharmacodynamics, clinical efficacy, and toxicity. Additionally, the review provides an extensive analysis of the representative synthetic techniques employed. Overall, this review emphasizes the significance of incorporating fluorine chemistry into anti-cancer drug research while highlighting promising future prospects for exploring compounds enriched with fluorine in the battle against cancer.
引用
收藏
页数:22
相关论文
共 127 条
  • [1] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
    Abou-Alfa, Ghassan K.
    Sahai, Vaibhav
    Hollebecque, Antoine
    Vaccaro, Gina
    Melisi, Davide
    Al-Rajabi, Raed
    Paulson, Andrew S.
    Borad, Mitesh J.
    Gallinson, David
    Murphy, Adrian G.
    Oh, Do-Youn
    Dotan, Efrat
    Catenacci, Daniel, V
    Van Cutsem, Eric
    Ji, Tao
    Lihou, Christine F.
    Zhen, Huiling
    Feliz, Luis
    Vogel, Arndt
    [J]. LANCET ONCOLOGY, 2020, 21 (05) : 671 - 684
  • [2] Adefovir, 2012, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
  • [3] Avapritinib for metastatic or unresectable gastrointestinal stromal tumors
    Alzofon, N.
    Jimeno, A.
    [J]. DRUGS OF TODAY, 2020, 56 (09) : 561 - 571
  • [4] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) : 1929 - 1940
  • [5] [Anonymous], 2006, Alpelisib, Drugs and Lactation Database (LactMed)
  • [6] Arguelles Delgado A. J., 2022, Patent No. [WO2022056100A1, 2022056100]
  • [7] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    [J]. BLOOD, 2018, 132 (24) : 2546 - 2554
  • [8] Propanephosphonic Acid Anhydride (T3P®) - A Benign Reagent for Diverse Applications Inclusive of Large-Scale Synthesis
    Basavaprabhu
    Vishwanatha, T. M.
    Panguluri, Nageswara Rao
    Sureshbabu, Vommina V.
    [J]. SYNTHESIS-STUTTGART, 2013, 45 (12): : 1569 - 1601
  • [9] Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
    Bauer, Sebastian
    Heinrich, Michael C.
    George, Suzanne
    Zalcberg, John R.
    Serrano, Cesar
    Gelderblom, Hans
    Jones, Robin L.
    Attia, Steven
    D'Amato, Gina
    Chi, Ping
    Reichardt, Peter
    Meade, Julie
    Su, Ying
    Ruiz-Soto, Rodrigo
    Blay, Jean-Yves
    von Mehren, Margaret
    Schoffski, Patrick
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6333 - 6342
  • [10] Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
    Benner, Brooke
    Good, Logan
    Quiroga, Dionisia
    Schultz, Thomas E.
    Kassem, Mahmoud
    Carson, William E.
    Cherian, Mathew A.
    Sardesai, Sagar
    Wesolowski, Robert
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 1693 - 1704